Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A hereditary spastic paraplegia that has material basis in variation in the chromosome region 10q22.1-q24.1.
Features include very common findings: Babinski sign, Lower limb hyperreflexia, Impaired vibration sensation at ankles, and Spastic/hyperactive bladder and others; and sometimes findings: Dysarthria, Dysdiadochokinesis, and Abnormality of somatosensory evoked potentials. 10 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 6 | Babinski sign, Lower limb hyperreflexia, Dysarthria |
Biomarker and diagnostic research for hereditary spastic paraplegia 27 has been reported in the published literature.
Phenotype severity distribution: 5 very common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for hereditary spastic paraplegia 27.
19 publications have been identified in PubMed for hereditary spastic paraplegia 27. Research spans Case Report / Case Series (26%), Epidemiology / Natural History (26%), and Diagnostic / Biomarker (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 5 | 26% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 11:56 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Arms and legs | 2 | Lower limb hyperreflexia, Lower limb spasticity |
Ears | 1 | Inner ear hearing loss (sensorineural hearing impairment) |
Disease patterns and progression
5 |
26% |
Testing and diagnosis research | 2 | 11% |
Clinical study results | 2 | 11% |
Laboratory research | 2 | 11% |
New treatment approaches | 2 | 11% |
Research summaries | 1 | 5% |
Allen MD (2026). [PMID: 41592170](https://pubmed.ncbi.nlm.nih.gov/41592170/). *Amyotroph Lateral Scler Frontotemporal Degener*. [Review / Meta-Analysis]
Resch D (2026). [PMID: 41328529](https://pubmed.ncbi.nlm.nih.gov/41328529/). *Mov Disord*. [Epidemiology / Natural History]
Finsterer J (2026). [PMID: 41496376](https://pubmed.ncbi.nlm.nih.gov/41496376/). *Am J Case Rep*. [Case Report / Case Series]
Choi Y (2026). [PMID: 41431411](https://pubmed.ncbi.nlm.nih.gov/41431411/). *Yonsei Med J*. [Epidemiology / Natural History]
Gillesse EH (2026). [PMID: 41656397](https://pubmed.ncbi.nlm.nih.gov/41656397/). *Neurogenetics*. [Case Report / Case Series]
Kessler C (2026). [PMID: 40961460](https://pubmed.ncbi.nlm.nih.gov/40961460/). *Amyotroph Lateral Scler Frontotemporal Degener*. [Epidemiology / Natural History]
Akinfiev VM (2026). [PMID: 41930429](https://pubmed.ncbi.nlm.nih.gov/41930429/). *Zh Vopr Neirokhir Im N N Burdenko*. [Clinical Trial Publication]
Thatikala A (2026). [PMID: 41505685](https://pubmed.ncbi.nlm.nih.gov/41505685/). *Neurology*. [Case Report / Case Series]
Wiora L (2025). [PMID: 40741602](https://pubmed.ncbi.nlm.nih.gov/40741602/). *Mol Ther Methods Clin Dev*. [Gene Therapy / Novel Therapeutics]
Alecu JE (2025). [PMID: 39731469](https://pubmed.ncbi.nlm.nih.gov/39731469/). *Genet Med*. [Epidemiology / Natural History]